第十届亚太地区循证医学研讨会召开,推动循证中医药学发展

2018-10-25 董俊彤 中国中医

以“循证医学的新时代”为主题的第十届亚太地区循证医学研讨会、第三届循证中医药学国际论坛暨首届世界人工智能健康管理论坛在天津举办。此次会议将循证医学、中医药学和人工智能三个领域跨界融合在同一学术平台,探讨了“EBM+TCM+AI”三位一体发展模式,将为慢病防控和健康管理贡献新的思路和智慧,在行业内具有重要意义。

以“循证医学的新时代”为主题的第十届亚太地区循证医学研讨会、第三届循证中医药学国际论坛暨首届世界人工智能健康管理论坛在天津举办。此次会议将循证医学、中医药学和人工智能三个领域跨界融合在同一学术平台,探讨了“EBM+TCM+AI”三位一体发展模式,将为慢病防控和健康管理贡献新的思路和智慧,在行业内具有重要意义。

国家“重大新药创制”科技重大专项技术总师桑国卫院士,中华中医药学会会长王国强,中国中医科学院院长、天津中医药大学校长张伯礼院士出席会议

据悉,循证医学发展的基础是科学快速处理海量健康和医学相关信息,生产复杂问题综合干预证据的创新方法学、标准、规范、流程、决策建议和实践指南;在确保信息安全的前提下,与大数据挖掘和人工智能分析利用新技术深度融合,才能实现高质量证据的优质高效生产、存储、共享和及时转化应用和持续改进。中西医并重、中西药并用是我国医疗实践的显着特点,也是循证中医药学创新发展的立足点和重点。循证医学与中医药学、信息技术融合发展体现的是中国特色、现实需求和未来方向。

王国强在讲话中指出,中医药学在几千年的临床实践中,总结出了丰富的经验和经典名方,形成了系统且先进的医学理论。近十年来,循证医学与中医药学在实践中从碰撞走向融合,发展形成了循证中医药学学科。通过借鉴循证医学的理念和方法,收集、评价、生产、转化中医药有效性、安全性和经济性的证据,揭示中医药临床作用的特点和规律,并指导临床指南、路径和卫生决策的制定,推动了中医药研究的发展。

王国强提出,今后应从几方面推动循证中医药学的发展。一是要切实地加强队伍建设;二是要切实地探索适应中医药特点和辩证论证模式的中医药临床评价方法学;三是要切实注重证据的转化,开展证据转化研究,为制定中医药临床指南和临床路径。为基本药物目录和医保目录的遴选及中医药相关政策的制定奠定基础;四是要切实地挖掘和发挥中医非药物疗法的优势;五是要切实地推动中医药国际化的发展,实施标准化引领国际化策略,做好中医药海外中心在“一带一路”沿线国家的布局,让更多的中医中心由点成线,打造中医药健康“一带一路”。

国家中医药管理局科技司司长李昱表示,中医药在中国乃至于在世界医疗保健产业中都占有重要的地位,但疗效证据质量不高阻碍了中医药国际化进展。循证医学的兴起,带来了解决问题的理念和方法,对中医药现代化、国际化进程都起到了积极的促进作用。科技部重大专项司邱钢表示,中医药需要与循证医学、信息技术融合发展,更重要的是,只有与中医药的独特优势和原创思维结合,医疗领域科技创新才更具有中国特色和原创优势,也更能为世界生命科学发展和健康管理贡献中国智慧和中国方案。

大会还发布了《循证中医药学》《实用循证医学》着作和《新时代循证医学发展天津宣言》;同时,由天津中医药大学循证医学中心研制的中药临床证据库正式运行,循证中医药研究联盟发布了中药注射剂临床有效性证据指数。为表彰中国循证医学中心主任李幼平教授对我国循证医学做出的杰出贡献,大会学术委员会授予李幼平“循证医学终身成就奖”。《循证中医药学》首次对中医药循证评价20年发展的成果进行了系统总结,是循证医学中国发展的一项标志性成果。专着主编是天津中医药大学张俊华教授和四川大学华西医院孙鑫教授,李幼平和张伯礼担任主审,陈可冀题写书名。

本次大会由四川大学华西医院、天津中医药大学、中国科学院微电子研究所共同主办,由中国循证医学中心、中意中医药联合实验室、中国循证医学杂志、JournalofEvidence-BasedMedicine、中国临床试验注册中心、天津中医药大学循证医学中心、天津市中西医结合学会循证医学专业委员会联合承办。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2019-06-30 kcb069
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-27 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-27 xjy04
  6. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-26 运动yd

    中医中药,大多被人诋毁,不过梅斯里总是客观公正的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1687577, encodeId=133f168e577ea, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Thu May 23 14:38:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994813, encodeId=d1ac199481317, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Jun 30 11:38:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379468, encodeId=42d513e94689e, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409699, encodeId=8305140969924, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449772, encodeId=7cc31449e72b0, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543339, encodeId=83b71543339ae, content=<a href='/topic/show?id=0dc224246b2' target=_blank style='color:#2F92EE;'>#亚太地区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24246, encryptionId=0dc224246b2, topicName=亚太地区)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=539b13566968, createdName=ms5439512287675881, createdTime=Sat Oct 27 12:38:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049570, encodeId=edef10495e007, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Oct 26 00:38:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350511, encodeId=979635051185, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 25 22:03:22 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-25 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

相关资讯

增长80%!2018年亚太地区医疗并购将达550亿美元

得益于大型制药公司疯狂抢购廉价生产基地,预计2018年亚太地区的医疗保健并购(M&A)总额将增长80%,达到551亿美元。

亚太地区心血管介入治疗数据及发展趋势

       在第十届中国介入心脏病学大会(CIT)的全体大会以庆祝亚太地区成为心血管介入治疗学新兴中心为主题。基于此,在大会共同主席Martin B Leon的主持下,通过对数据的比较和分析,来自亚太10个国家或地区(澳大利亚、中国、中国香港、印度、印度尼西亚、日本、马来西亚、新加坡、韩国、泰国)的专家共同讨论了亚太地区心血管介入治疗的现状、变化趋势、差异

亚太地区22亿人面临罹患疟疾风险

  世界卫生组织与遏制疟疾伙伴关系11月2日发布的一份最新报告显示,亚太地区共有近22亿人生活在受疟疾感染的阴影之下,2010年亚太地区共有约3000万个新发疟疾病例,由此导致的死亡人数超过4万2000人。   世卫组织和遏制疟疾伙伴关系在2日在澳大利亚悉尼举行的“疟疾2012大会”上发布了的名为《在亚洲、太平洋、美洲、中东和欧洲战胜疟疾》的报告阐述了疟疾对非洲以外国家的发展和卫生事业所造成的影

疟疾2012大会:拯救亚太地区的生命

  2012年10月31日至11月2日,疟疾2012大会在澳大利亚悉尼召开。疟疾2012大会旨在加快全球目标方面的进展,即到2015年使亚太地区的疟疾病例和死亡数减少75%。   疟疾2012大会的会议日程侧重于在亚太地区控制并消除疟疾的重要因素。这些因素包括诸如可持续性筹资、政治领导力以及区域合作等问题。与疟疾控制和消除相关的许多挑战与其它公共卫生威胁存有共同之处。   本次大会汇集区域性政

Int Arch Allergy Immunol:亚太地区慢性呼吸道疾病的医疗模式研究

过敏性鼻炎(AR)、哮喘、慢性阻塞性肺病(COPD)和鼻窦炎是常见的疾病,但是在亚太地区却鲜有研究。最近,有研究人员调查了这些呼吸道疾病在印度、韩国、马拉西亚、新加坡、泰国以及中国台湾的真实世界医疗模式情况。研究发现,总共筛选了13902名患者,7243(52%)名患者为AR(18%)、哮喘(18%)和COPD(7%)以及鼻窦炎(9%)。该7243名患者中的5250(72%)名患者符合研究的要求。